Viedoc Technologies
Viedoc Technologies is recorded as a service provider in 57 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 57 trials · Latest update first
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A phase IV randomised, parallel-group, double-blinded, placebo-controlled, trial evaluating the efficacy of the tree SLIT-tablet in adolescents (12-17 years of age) with allergic rhinitis/allergic rhinoconjunctivitis induced by birch pollen using an environmental exposure unit.
Sponsor Alk-Abello A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
BEACON2: A multi-arm multi-stage platform trial for relapsed neuroblastoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomised, open label, multicentre study of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Sponsor Oncoinvent Solutions AS
- Start (EU)
- Latest update
- Estimated end
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
Sponsor Ribocure Pharmaceuticals AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide. A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
Sponsor Urogen Pharma Ltd.
- Start (EU)
- Latest update
- Estimated end
A Pivotal, Randomized, Placebo-Controlled, Double-Blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)
Sponsor Rheacell GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer
Sponsor OncoZenge AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma
Sponsor Acrotech Biopharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia
Sponsor Agiana Pharmaceuticals AS
- Start (EU)
- Latest update
- Estimated end
- Not reported
Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
Sponsor Rare Thyroid Therapeutics International AB
- Start (EU)
- Latest update
- Estimated end
A phase II study evaluating the efficacy and safety of imetelstat in patients with HR myelodysplastic syndromes or AML failing HMA-based therapy
Sponsor Gcp-Service International West GmbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The interim analysis of the first 21 evaluable patients identified no primary-endpoint responders; the dosing schedule was amended and subsequent efficacy analyses continued exploratorily.
- High early discontinuation and death rates resulted in limited evaluable efficacy data, and substantial missing data added uncertainty to the results.
- Delayed serious-adverse-event reporting occurred because several sites were uncertain whether progression to AML met serious-adverse-event reporting criteria.
These findings describe the trial, not the service provider’s performance or responsibility.
Local and systemic safety and tolerability of ascending doses of TOP-N53, a nitric oxide (NO)-releasing phosphodiesterase-5 (PDE5) inhibitor, administered topically, on wound in patients with digital ulcers (DU) in systemic sclerosis (SSc) in an open-label, vehicle-controlled, phase 2a, multi-center clinical trial
Sponsor Topadur Pharma Deutschland GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Sponsor Phenonet Inc.
- Start (EU)
- Latest update
- Estimated end
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside standard-of-care endocrine treatment in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment (CAPIcorn)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Viedoc Technologies?
The 2026-10-09 snapshot links Viedoc Technologies to 57 distinct CTIS trials. Recorded services include Electronic data capture, Interactive response technology (IRT), eCRF, Clinical outcome assessments, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Viedoc Technologies?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Haematological Malignancies, Cardiology, Dermatology. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Viedoc Technologies conducted?
The linked trials record locations in 24 countries, including Germany, Spain, Portugal, France, Italy. These are trial locations, not confirmed office locations or countries where Viedoc Technologies delivered services.
What can this page tell me about Viedoc Technologies's trial experience?
Browse 57 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Viedoc Technologies. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Viedoc Technologies AB